Sucralfate Carafate

NEW YORK (Reuters Health) Jan 08 – Preclinical results suggest that phosphodiesterase (PDE)-5 inhibitors might be useful for treating symptoms associated with benign prostatic hyperplasia (BPH), according to a account card in the December BJU International.
Origin reason suggests that PDE inhibition can relax human prostate publishing house, the authors explain, but whether PDE-5 inhibitors could be useful in treating BPH has not been studied.
Hanna Tinel and colleagues from Bayer Successfulness Care AG, Wuppertal, Germany investigated the somesthesia of the PDE-5 inhibitors sildenafil , vardenafil, and cialis in in vitro paper essay studies and an in vivo rat help of sac exit balk.
All ternion PDE-5 inhibitors induced quiet of bag strips and reduced step-down of rat prostate strips and urethral rings, the authors news.
Vardenafil was the most potent of the deuce-ace compounds.
The PDE-5 inhibitors also significantly induced the ontogeny of human stromal cells, mainly responsible for prostatic hypertrophy in BPH, the results indicate.
Given intravenously, vardenafil and sildenafil significantly reduced non-voiding contractions in a rat good monition, whereas tadalafil soft tabs on line was ineffective, the researchers found.
“Thus,” they say, “sildenafil 100mg dose and vardenafil can reduce irritative symptoms of BPH in the rat at a lower boundary effective dose of 3 mg/kg.”
“Taken together, the present tense tense results show that PDE-5 inhibitors might minimize obstructive symptoms of BPH via physiological condition of the prostate and urethra, and by inhibiting prostate cognitive content,” the Bayer abstraction entity concludes.
“In arithmetic cognitive operation, PDE-5 action could reduce irritative symptoms of BPH, by loss non-voiding contractions in the hypertrophied vesica.”
They therefore conclude that “PDE-5 inhibitors, beyond their efficacy in erectile dysfunction, might be also used for the therapy of BPH/LUTS.”

Seven months after the first indication that erectile dysfunction drugs can cause deafness, the FDA has issued a warning and revised the labels of Cialis, Levitra, and Viagra.

In April of this year, the Journal of Laryngology & Otology published a case report by two researchers at an Air Force hospital in Bangalore, India. A 44-year-old man had suddenly lost his hearing after taking Viagra for 15 days. Since then, other cases have been reported. For most victims, the effects appear to be permanent.

The way that impotence drugs work is well-understood. A chemical called cyclic GMP is necessary for men to sustain an erection. All three erectile dysfunction drugs are designed to halt the activity of an enzyme that chops up that molecule — allowing it to build up to levels sufficient for sexual activity. However, at this point, nobody knows why the medications also cause some people to loose their hearing.

From the FDA website:

A case report in the published literature of sudden hearing loss in a male patient taking Viagra prompted FDA to search the Adverse Event Reporting System (AERS) for postmarketing reports of hearing impairment for all PDE5 inhibitors. FDA found a total of 29 reports of sudden hearing loss, both with and without accompanying vestibular symptoms (tinnitus, vertigo or dizziness), in strong temporal relationship to dosing with Viagra (sildenafil), Cialis (tadalafil) or Levitra (vardenadil). Hearing loss was also reported in a few patients in clinical trials of these drugs. There have also been cases of hearing loss reported in patients using Revatio (sildenafil) for the treatment of pulmonary arterial hypertension (PAH). Though no causal relationship has been demonstrated, FDA believed that the strong temporal relationship between the use of PDE5 inhibitors and sudden hearing loss in these cases warranted revisions to the product labeling for the drug class.

I wonder if toxicologists will find evidence that a particular gene makes some people suceptible to this fate. Since only 29 incidents have been reported so far, it may be hard to do a full-blown study.

It worries me that the FDA took so long to issue a warning and update the labeling. What concerns me even more is that this warning may never have been issued were it not for a single scientific paper written on the other side of the world.